Quick summary: Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia .
Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia
Recommended action: compare your product with the official notice and follow the instructions published by the official source.
Recall details
Quick summary: Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia .
Affected product details
Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.
Affected products
Issue
Janssen COVID-19 Vaccine was authorized for use in Canada on March 5, 2021 in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Since the time of authorization, there have been very rare reports of thrombosis with thrombocytopenia following administration of Janssen COVID-19 Vaccine.
What you should do
Additional official information
Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.
Frequently asked questions
Answers based on the official recall notice.
Product images
Official product images from Health Canada.
Starting...
Explore more
Related recalls
Similar recalls and safety notices.